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Abstract
Background and study aims—The impact of the diagnosis and treatment of dysplastic
Barrett’s esophagus (BE) on quality of life (QoL) is poorly understood. This study assessed the
influence of dysplastic BE on QoL and evaluated if endoscopic treatment of dysplastic BE with
radiofrequency ablation (RFA) improves QoL.
Patients and methods—We analyzed changes in QoL in the AIM Dysplasia Trial—a
multicenter study of patients with dysplastic BE randomized to RFA therapy or a sham
intervention. We developed a 10-item questionnaire to assess the influence of dysplastic BE on
QoL. The questionnaire was completed by subjects at baseline and 12 months.
Results—One hundred and twenty-seven patients were randomized to RFA (n=84) or sham
(n=43). At baseline, the majority of subjects reported esophageal cancer worry (71% RFA, 85%
sham) and esophagectomy worry (61% RFA, 68% sham). Subjects reported depression, impaired
QoL, worry, stress and dissatisfaction with the condition of their esophagus. Of those randomized,
117 subjects completed the 12 month endpoint. Compared to sham, subjects treated with RFA had
significantly reduced esophageal cancer worry (p=0.003) and esophagectomy worry (p=0.009).
They also had significantly reduced depression (p=0.02), general worry with the condition of their
esophagus (p≤0.001), impact on daily QoL (p=0.009), stress (p=0.03), dissatisfaction with the
condition of their esophagus (p≤0.001) and impact on work and family life (p=0.02).
Conclusions—Inclusion in the treatment group of this randomized, sham-controlled trial of
RFA was associated with improvement in disease-specific health-related quality of life. This
improvement appears secondary to a perceived decrease in the risk of cancer.
Barrett’s esophagus (BE) is a metaplastic change in the lining of the esophagus from
stratified squamous epithelium to specialized columnar epithelium.[1] This intestinal
metaplasia may progress through low-grade (LGD) and high-grade dysplasia (HGD) to
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esophageal adenocarcinoma. Intestinal metaplasia is associated with an approximately 0.5%
per patient-year risk of developing esophageal adenocarcinoma. For patients with high-grade
dysplasia, this risk increases to 5–10% or more per patient-year.[2–5] Esophageal
adenocarcinoma has a 5-year survival rate of less than 15%.[6]
QoL has been defined as “those attributes valued by patients, including their resultant
comfort or sense of well-being; the extent to which they were able to maintain reasonable
physical, emotional, and intellectual function; and the degree to which they retain their
ability to participate in valued activities within the family, in the workplace, and in the
community.”[7] Several investigators have assessed quality of life (QoL) in patients with
BE. A diagnosis of BE with intestinal metaplasia is associated with a decrease in QoL on
generic and organ system-specific measures, along with increased health care cost and
increased health care utilization.[8] To date, no studies have evaluated QoL in patients with
dysplastic BE. In contrast to patients with intestinal metaplasia, patients with dysplastic BE
may feel additional anxiety about their risk of developing cancer. Further, management of
dysplastic BE requires close follow-up, repeat endoscopy, and invasive procedures.
Financial stress may also be greater—a BE diagnosis has been shown to cause increases in
life insurance premiums and restricts the availability of health insurance.[9]
Historically, BE with HGD was treated with esophagectomy, a procedure associated with
significant morbidity and some mortality.[10] The impact of esophagectomy on QoL in
HGD has been rarely studied.[11–13] Endoscopic ablation has evolved as a less invasive
alternative to esophagectomy. Successful endoscopic eradication of BE is associated with a
decreased risk of esophageal adenocarcinoma; however, the effect of successful endoscopic
treatment of dysplastic BE on QoL is not known. [3,14] To evaluate QoL before and after
endoscopic treatment of dysplastic BE with radiofrequency ablation (RFA), we have
performed an analysis of QoL in the AIM Dysplasia Trial.[14]
Methods
Parent Study Design
The AIM Dysplasia Trial is a multicenter, randomized, sham-controlled study of patients
with BE and low- or high-grade dysplasia. Patients were randomized to receive RFA therapy
plus endoscopic surveillance or a sham intervention plus surveillance. A detailed description
of the study methods have been reported, but are described here in brief.[14] Patients were
considered for study inclusion if they were between the ages of 18 and 80 years and had 8
cm in length or less of non-nodular dysplastic BE. All patients with high grade dysplasia
were required to have an endoscopic ultrasonography examination negative for
lymphadenopathy and esophageal-wall abnormalities within 12 months of enrollment.
Endoscopic mucosal resection 8 weeks or more prior to study enrollment was permitted if
subsequent endoscopy demonstrated non-nodular dysplasia. Exclusion criteria were
pregnancy, active esophagitis or stricture precluding passage of the endoscope, a history of
esophageal cancer, esophageal varices, uncontrolled coagulaopathy, or a life expectancy of
less than 2 years as judged by the site investigator. All management options including
conservative management and esophagectomy were reviewed with all patients who provided
written informed consent.
Subjects were randomly assigned in a 2:1 ratio with the use of computer-generated block-
randomization to receive either RFA or a sham endoscopic procedure, stratified by degree of
dysplasia (high-grade dysplasia (HGD) & low-grade dysplasia (LGD)). All subjects had an
upper endoscopy, esophageal intubation with a study catheter and measurement of the
esophageal inner diameter. Among subjects in the ablation group, the entire segment of BE
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was ablated. Among those in the control group, the study catheter was removed and the
procedure was terminated.
Subjects in the ablation arm received up to four endoscopic RFA treatments (HALO360 and
HALO90, BÂRRX Medical, Sunnyvale, CA). All subjects received esomeprazole 40 mg
twice daily (AstraZeneca, LLP, Wilmington, DE) throughout the study. All subjects
underwent endoscopic surveillance at 3 month (HGD cohort) or 6 month (LGD cohort)
intervals. The primary outcomes at 12 months were complete eradication of dysplasia and
complete eradication of intestinal metaplasia.[14]
The study protocol was approved by each site’s Institutional Review Board. All subjects
gave written informed consent. The study was monitored by an independent data and safety
monitoring committee. The parent study was supported by BÂRRX Medical, maker of the
ablation devices used in the protocol. Study medication was provided by AstraZeneca.
Support for the preliminary work for the quality of life tool (patient interviews, interview
coding and analysis) was provided by NIH R03 DK075842 & NIH P30 DK56350.
Statistical analysis and data management were supported by NIH P30 DK034987 & NIH
T32 DK 07634.
Assessment of QoL
At baseline, each subject completed a self-administered BE QoL questionnaire (Figure 1).
Because subjects may misunderstand the current condition of their esophagus, and because
quality of life may depend on the subjects’ perception of their condition more so than the
actual disease state, subjects also answered a question asking their understanding of the
current disease state of their esophagus, with choices including normal esophagus, non-
dysplastic BE, BE with LGD, BE with HGD or BE with cancer. Subjects were then
randomized to RFA or sham and received care as detailed above. After the 12 month
endoscopy, the subject was contacted by study site personnel and their 12 month esophageal
biopsy results were disclosed and discussed. Thereafter, the subject again completed the BE
QoL questionnaire and again reported their perceived disease state as above. The
randomization group to which the patient was assigned (RFA vs. sham) was revealed only
after the completed BE QoL questionnaire was received.
QoL Questionnaire Development
No validated quality of life measure for BE exists, and measures designed to assess QoL in
GERD may miss important domains of QoL in BE. For that reason, we assessed factors
impacting QoL in BE. Twenty-five subjects with BE underwent one-on-one interviews with
three individuals skilled in qualitative research. These interviews solicited areas of most
concern for subjects, and queried the impact of the diagnosis of BE on the subject’s QoL.
After thematic saturation had been reached (no new themes were identified), interviews
were coded using a qualitative data analysis program, and summary frequency tables of
patient concerns were created. A questionnaire was developed based on relevant QoL
domains and recurrent thematic responses to the interviews encompassing areas commonly
identified by patients as sources of reduction in QoL (Figure 1). This questionnaire consists
of 2 yes/no questions, and 8 visual analog scale questions. Pilot testing suggested it was
easily understood by patients, and responsive to changes in the subjects’ condition.
Statistical Analysis
Means and standard deviations are reported for continuous variables. Proportions are
reported for categorical data. To compare RFA and sham subject’s baseline characteristics,
we used a 2 sample t-test, the Pearson’s chi-square test or the Fisher’s Exact Test, as
appropriate. To compare RFA and sham baseline QoL scores, we used the Pearson’s chi-
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square for categorical QoL outcomes and Wilcoxon Rank-sums for continuous QoL
outcomes. To further assess the impact of dysplastic BE on QoL, baseline QoL scores were
stratified by sex, age, race, dysplasia grade, BE length, and BMI. The stratified analysis was
performed with the Fisher’s Exact test and Wilcoxon Rank-sums for categorical variables
and Spearman Correlation for continuous variables. To perform bivariate analyses
comparing QoL at 12 months based on the outcome of treatment, we used the Fisher’s Exact
test for categorical QoL outcomes and Wilcoxon Rank-sums for continuous QoL outcomes.
We performed bivariate analyses to assess the impact of RFA and subject’s histology
findings at 12 months on QoL. Seven analyses were performed. The first analysis compared
the RFA group to the sham group. The second analysis compared the RFA group achieving
complete eradication of intestinal metaplasia to the sham group. The next analysis compared
the RFA group without complete eradication of intestinal metaplasia to the sham group. The
fourth analysis compared the RFA group with complete eradication of intestinal metaplasia
to the RFA group with incomplete eradication of intestinal metaplasia. Analyses 5–7were
repeats of analyses 2–4, however, in these three analyses patients were classified using their
self-reported perceived disease state as opposed to their actual pathology results.
All tests of significance were two-tailed and alpha values <0.05 were considered significant.
No adjustments for multiple comparisons were made. Quantitative analyses were performed
with SAS software, version 9.0 (SAS Institute).
Results
Seven hundred and fifty-five patients were screened for participation and 127 patients met
study criteria and were randomized to RFA or sham procedure (Figure 2). Of those
randomized, 117 subjects completed the 12 month endoscopy (primary endpoint). In brief,
in an intention to treat analysis, we found that among subjects with LGD, 90.5% of those in
the RFA group had complete eradication of dysplasia compared with 22.7% of those in the
sham group. Among subjects with HGD, 81.0% of those in the RFA group had complete
eradication of dysplasia compared with 19.0% of those in the sham group. Among all
subjects, 77.4% of those in the RFA group had complete eradication of intestinal metaplasia
compared to 2.3% of those in the sham group (p<0.01 for all). By the 12 month endoscopy,
1 subject in the RFA group and 4 subjects in the sham group progressed to esophageal
adenocarcinoma (1.2% vs. 9.3%, p<0.05).
QoL and Dysplastic BE
At baseline, QoL data was collected on the 127 subjects who met study criteria and were
enrolled (intent-to-treat population). Subject demographics and characteristics are detailed in
Table 1. At baseline, the majority of subjects reported worry that they would develop
esophageal cancer (71% RFA, 85% sham) and worry that they would need an
esophagectomy (61% RFA, 68% sham) (Table 2). Given the present state of their
esophagus, subjects also reported worry, depression, impaired QoL, stress and
dissatisfaction with their esophagus (Table 2). Randomization was successful, in that QoL
scores did not differ significantly between the RFA and the sham group (Table 2).
At baseline, women reported a trend toward greater worry that they would develop
esophageal cancer than men (94% versus 73%, respectively; p=0.07). Given the present state
of their esophagus, women also reported greater worry with the condition of their esophagus
(p=0.02), impact on daily QoL (p=0.004) and difficulty with sleep (p=0.03). Increasing age
was associated with less esophageal cancer worry (p=0.03) and esophagectomy worry
(p=0.04). Increasing age was also associated with less worry with the condition of their
esophagus (p≤0.001), depression (p=0.005), amount of stress (p=0.009), difficulty with
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sleep (p=0.005) and concern regarding dying (p=0.03). Increasing BMI was positively
correlated with depression (p=0.02), dissatisfaction with the condition of the esophagus
(p=0.02) and difficulty with sleep (p=0.007). Grade of dysplasia, race and BE length was not
associated with a statistically significant difference in QoL scores at baseline.
QoL and Dysplastic BE status post RFA
Of the subjects randomized, 117 completed the 12 month endoscopy (Figure 2). One subject
in the RFA group and 4 subjects in the sham group progressed to esophageal
adenocarcinoma, leaving 112 subjects available for the current QoL analysis. After the 12
month endoscopy, patients were informed of the disease state of their esophagus (normal
esophagus, non-dysplastic BE, BE with LGD, BE with HGD or BE with cancer). However,
after being given this information, only 59% of subjects correctly reported their current
disease state while 32% reported an upgraded diagnosis and 9% a downgraded diagnosis
(Table 3). Disease misclassification did not differ by gender or treatment type.
Compared to the sham group, subjects treated with RFA had improved QoL (Table 4).
Specifically, they demonstrated significantly reduced worry that they would develop
esophageal cancer (p=0.003) and worry that they would need an esophagectomy (p=0.009)
(Table 4). They also had significantly reduced worry about the present condition of their
esophagus (p≤0.001), depression (p=0.02), impact on daily QoL (p=0.009), stress (p=0.03),
dissatisfaction with the condition of their esophagus ( p≤0.001) and impact on work and
family life (p=0.02) compared to sham. Similar results were obtained when we performed
the same analysis comparing subjected treated with RFA achieving complete eradication of
intestinal metaplasia to the sham group (Table 5) and when comparing those who believed
they had achieved complete eradication of intestinal metaplasia to the sham group (Table 5).
Compared to the sham group, subjects in the RFA group who did not achieve complete
eradication of intestinal metaplasia still had improvement in multiple domains. Specifically,
they demonstrated significantly reduced worry that they would develop esophageal cancer
(p=0.03), a significant reduction in stress (p=0.05) and dissatisfaction with the condition of
their esophagus (p=0.04) (Table 6). The same analysis performed with subject perceived
pathology demonstrated that subjects treated with RFA who reported incomplete eradication
of intestinal metaplasia compared to the sham group had significantly reduced worry that
they would develop esophageal cancer (p≤0.001) and worry that they would need an
esophagectomy (p=0.01) (Table6). They also had a significant reduction in worry about the
present condition of their esophagus (p=0.005), as well as trends toward improvement in
dissatisfaction with their esophagus (p=0.06) and impact on work or family life (p=0.05)
(Table6).
Subjects in the RFA group who had complete eradication of intestinal metaplasia compared
to those in the RFA group with incomplete eradication of intestinal metaplasia had
significantly reduced worry about the present condition of their esophagus (p=0.03), but no
other differences on the other nine areas queried (Table7). The same analysis, performed
with subject perceived pathology demonstrated that subjects treated with RFA who reported
complete eradication of intestinal metaplasia compared to those treated with RFA who
reported incomplete eradication of intestinal metaplasia had significant reductions in worry
about the present condition of their esophagus (p=0.05) and dissatisfaction with their
esophagus (p=0.03) (Table7).
Discussion
While quality of life is among the most difficult research endpoints to measure, it is perhaps
the most important of all clinical outcomes. Much research to date in the treatment of BE
has focused on the methodologically simpler outcomes of morbidity and mortality. While
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most patients want to live longer, many of our patients are less interested in these outcomes
as we define them. Our patients want to feel better physically and mentally. They want to
live longer, but also to live well.
Our study found that the majority of patients with dysplastic BE report substantial worry
about cancer and the need for esophagectomy, as well as a negative impact on their quality
of life secondary to their diagnosis. Women appear to be disproportionately affected by the
condition, a finding common to multiple quality of life analyses of different disease states.
[15] Regardless of final histological diagnosis, randomization to the RFA group was
associated with improvement in QoL (Table4). Not surprisingly, subjects who underwent
successful endoscopic RFA resulting in complete eradication of intestinal metaplasia had
marked improvement in QoL as compared to subjects undergoing a sham procedure.
Specifically, these subjects reported significant decreases in worry that the present condition
of their esophagus would result in the development of cancer and future need for an
esophagectomy. They also reported decreased symptoms of general worry relative to the
present condition of their esophagus, depression, and stress along with improved satisfaction
with their esophagus. Work and family life were improved as was overall daily QoL.
Most subjects (77%) randomized to the RFA group achieved complete eradication of all
intestinal metaplasia, accounting for the improvement in QoL seen in the treatment arm. The
majority of RFA-treated subjects who did not achieve complete eradication of intestinal
metaplasia had downgrading of their disease, with eradication of dysplasia. Because non-
dysplastic BE presumably has a lower risk of progression to cancer, it is not surprising that
these subjects with incomplete eradication of IM also reported a significant decrease in
worry that the present condition of their esophagus would result in the development of
cancer and had reduced general worry, dissatisfaction with the condition of their esophagus,
and impact on work or family life as compared to subjects who underwent sham procedure.
There were few significant differences in QoL when comparing those treated with complete
eradication of IM to those treated without complete eradication of IM. Because all subjects
treated with RFA had either complete eradication of IM or downgrading of disease, there
were significant improvements in QoL for the majority of subjects in the RFA group
compared to the sham group.
Perceived health is an important predictor of health outcomes, independent of clinical health
status.[16] In our population, a remarkable 41% of subjects misclassified the disease state of
their esophagus even after being informed of the results of their 12 month biopsies, with
most over-estimating their disease severity. The etiology of this misunderstanding is unclear
and deserves further study, but points to suboptimal communication between the physician
and the patient regarding this complex clinical situation. To assess the impact of this
misunderstanding of disease on our data, we performed an analysis using both actual
pathology and self-reported pathology. The magnitude and directionality of the impact of
treatment with RFA was largely unchanged in analyses using self-reported pathology. Our
data suggest that the positive impact of RFA therapy was largely secondary to manipulation
of the patients’ perceived risk of cancer. This is attested to by the observation that the
quality of life measures in subjects who wrongfully believed they were clear of BE were
similar to those of subjects who truly achieved a complete eradication of BE. While the
impact of RFA treatment on cancer mortality remains unclear, it is obvious that informing
subjects that their BE had been eradicated led to the logical belief that their chance of
developing or dying of cancer had been diminished.
The alternative to RFA for dysplastic BE is esophagectomy. Three studies have described
the impact of QoL after esophagectomy for dysplastic BE.[11–13] Each study
retrospectively assessed QoL approximately 5 years status post esophagectomy with the
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SF-36, a generic assessment of health related quality of life. All three studies found that the
cohort post-esophagectomy had SF-36 scores similar to or better then age- and sex-matched
US general population normal values.[11–13] In addition to the SF-36, Chang et al assessed
common post esophagectomy symptoms and found that 59% had reflux or regurgitation,
55% diarrhea, 45% bloating, 28% nausea, 28% dysphagia, 17% postprandial diaphoresis,
17% abdominal pain and 7% hoarseness.[12] There is a single retrospective cohort study of
QoL in patients with a history of dysplastic BE or intramucosal carcinoma status post
endoscopic ablation (photodynamic therapy, argon photo coagulation and or endoscopic
mucosal resection) compared to esophagectomy.[17] QoL was assessed with the SF-36 and
did not differ by treatment group in a model adjusted for age and gender.[17] It is unclear
why the SF-36 scores suggest no change in QoL post-esophagectomy while patients do
report the common post-esophagectomy symptoms noted above. This may result from the
use of generic instruments instead of disease specific instruments, which are designed to
identify issues that are important to patients with specific conditions as well as measure
clinically important changes from specific treatments.[18] There may also be selection bias
in these studies, in that only subjects well enough to undergo esophagectomy were included
in the intervention groups, and only those who survived the surgery were available later for
survey. Comparing such a cohort to the general population may not be appropriate.
To date, no validated quality of life measure for Barrett’s esophagus has been described in
the literature. Generic instruments may be insensitive to clinically significant changes
specific to BE. Given these concerns, we created a disease-targeted measure to assess
aspects of QoL in BE. This measure was constructed after conducting interviews to identify
areas of greatest concern for patients with BE. Disease specific measures, by design, usually
have adequate validity and reliability.[19] While the methodology used to develop our
instrument provides high content validity, the test-retest reliability of the instrument and
convergent validity have not been established. In addition, a reference timeframe was not
established in the questionnaire and may need adjustment based on the intervention
considered. Further work will be necessary to define the operating characteristics of this
tool. Finally, we chose not to adjust for multiple comparisons because each question
addressed a unique quality of life dimension.
In summary, our data suggest that the majority of patients with dysplastic BE report a
substantial negative impact on their QoL. Eradication of dysplasia by ablation leads to a
marked improvement in disease-related QoL in the first 12 months of treatment. The
durability of these changes will be assessed with serial follow-up of this cohort.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Patient Demographics and Characteristics
RFA Sham
Patients (n) 84 43
Age (yrs) -mean 66.1 ± 9.1 65.9 ± 8.5
Sex -no. (%)
 Female 14 (17%) 3 (7%)
 Male 70 (83%) 40 (93%)
Race -no. (%)
 White 78 (93%) 43 (100%)
 Black 3 (4%) 0 (0%)
 Latino 3 (4%) 0 (0%)
Body mass index -mean* 28.5 ± 4.9 31.3 ± 5.8
Length of Barrett's esophagus (cm) -mean 4.9 ± 2.2 5.0 ± 2.4
High grade dysplasia -no. (%) 42 (50%) 21 (49%)
Time since diagnosis of Barrett's esophagus (yrs) -mean 5.2 ± 4.5 4.8 ± 5.3
Time since diagnosis of dysplasia (yrs) -mean 2.1 ± 2.8 1.9 ± 2.7
RFA = Radiofrequency ablation
Means arereported as means plus-minus the standard deviation
*
p < 0.05 for the comparison between the RFA and sham group based on 2-sample t-test
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Table 2
Baseline Dysplastic BE QoL
RFA Sham
Patients (n) § 84 43
Esophagectomy, worry no. (% yes) 51 (61%) 28 (68%)
Adenocarcinoma, worry no. (% yes) 60 (71%) 35 (85%)
Worry – mean (0 = none to 100 = extreme) 44 ± 26 41 ± 23
Depression – mean (0 = none to 100 = extreme) 20 ± 23 21 ± 23
Daily QoL – mean (0 = no effect to 100 severe negative effect) 18 ± 20 18 ± 22
Amount of Stress – mean (0 = noneto 100 = severe stress) 22 ± 25 19 ± 23
Amount of Satisfaction – mean (0 = very satisfiedto 100 = very unsatisfied) 54 ± 31 61 ± 31
Difficulty to Sleep – mean (0 = disagreeto 100 = agree) 21 ± 25 24 ± 26
Work or Family Life Negatively Impacted – mean (0 = disagree to 100 = agree) 22 ± 25 23 ± 27
May Die Due to Esophagus – mean (0 = disagreeto 100 = agree) 24 ± 27 27 ± 27
RFA = Radiofrequency ablation
Means are reported as means plus-minus the standard deviation
p = not significant for all comparisons between RFA and Sham based on Pearson’s chi-square for categorical QoL outcomes and Wilcoxon Rank-
sums for continuous QoL outcomes.
§
2 Missing Values in Sham Arm
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Table 3
Subject Reported Disease Misclassification







Adenocarcinoma 4 100% NA 0%
High grade dysplastic BE 17 47% 0% 53%
Low grade dysplastic BE 15 80% 20% 0%
Nondysplastic IM 15 33% 53% 13%
Complete Eradication of IM 66 60% 40% NA
All Subjects 117 59% 32% 9%
BE = Barrett’s esophagus
IM = Intestinal metaplasia
NA = Not applicable
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Table 4
QoL after RFA compared to sham
RFA Sham p-value‡
Patients (n) 77 35
Esophagectomy, worry – % no at 12 months 83% 43% 0.009
Adenocarcinoma, worry – % no at 12 months 78% 34% 0.003
Worry – mean change frombaseline −24 ± 24 2 ± 30 ≤0.001
(0 = none to 100 = extreme)
Depression – mean change from baseline −10 ± 23 0 ± 25 0.02
(0 = none to 100 = extreme)
Daily QoL – mean change from baseline −10 ± 21 0 ± 28 0.009
(0 = no effect to 100 severe negative effect)
Amount of Stress – mean change from baseline −12 ± 24 −1 ± 24 0.03
(0 = none to 100 = severe stress)
Amount of Satisfaction – mean change from baseline −42 ± 37 −17 ± 30 ≤0.001
(0 = very satisfied to 100 = very unsatisfied)
Difficulty to Sleep – mean change from baseline −16 ± 23 −10 ± 24 NS
(0 = disagree to 100 = agree)
Work or Family Life Negatively Impacted – mean change from baseline −16 ± 25 −3 ± 24 0.02
(0 = disagree to 100 = agree)
May Die Due to Esophagus – mean change from baseline −14 ± 27 −6 ± 31 NS
(0 = disagree to 100 = agree)
NS = Not Significant
RFA = Radiofrequency ablation
QoL = Quality of life
CE-IM = Complete eradication of intestinal metaplasia
Means are reported as the mean plus-minus the standard deviation
§
comparison between RFA and Sham based on Fisher’s Exact test for categorical QoL outcomes and Wilcoxon Rank-sums for continuous QoL
outcomes
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